A Phase 3 interventional study of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hemoglobinuria, Paroxysmal by Novartis — 5 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Novartis.
Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, this one is the only one that started in 2023, is one of 5 in phase 3, and was the 8th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →5 of the 16 studies in Hemoglobinuria, Paroxysmal by Novartis are open now, in 8 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–99
Novartis Pharmaceuticals · Sites in Italy
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in China
Ages 18–80
Novartis Pharmaceuticals · Sites in United States
Ages 18–99
By country, each count listing its studies:
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2023.
This study's enrollment of 52 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 28 across the 8 interventional studies, 80 across the 7 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
2 of the studies in Hemoglobinuria, Paroxysmal by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06931691Novartis PharmaceuticalsA Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China | 2027-04-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switched from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.
This was a multicenter, single-arm, open label trial, with iptacopan treatment for 24 weeks in adult PNH patients.
This study was comprised of two periods:
After completion of the treatment period, participants who continued to benefit from the iptacopan treatment based on the study doctor's evaluation were able to join the Roll-over extension study (CLNP023C12001B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Iptacopan (LNP023) at a dose of 200 mg b.i.d. orally
Drug: Iptacopan
Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
Also known as: LNP023
Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority
Change in hemoglobin (Hb) levels as mean of visits between Day 126 and Day 168 compared to baseline. Baseline is defined as as the mean of three Hb assessments conducted at the central laboratory: two during screening and the third on Day 1. The estimation of change from baseline in Hb levels was handled by the hypothetical strategy where participants were assumed as if they did not receive RBC transfusions while on treatment (RBC transfusions were expected to be rare). Assuming that participants had stable Hb levels at study entry, the mean change from baseline in Hb level between Day 126 and Day 168 was expected to be unchanged should participants have continued on anti-C5 treatment. Non-inferiority of iptacopan was therefore tested by the null hypothesis (H0) against the alternate hypothesis (H1) comparing the mean change from baseline in Hb level in iptacopan between Day 126 and Day 168 (μ) to -1 g/dL: H0: μ \<= -1, H1: μ \> -1.
Time frame: Baseline, Day 126 to Day 168
Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Superiority
Change in hemoglobin (Hb) levels as mean of visits between Day 126 and Day 168 compared to baseline. Baseline is defined as as the mean of three Hb assessments conducted at the central laboratory: two during screening and the third on Day 1.
Time frame: Baseline, Day 126 to Day 168
Proportion of Hematological Responders to Iptacopan Treatment
Response defined as Hb ≥12 g/dL assessed between visits Day 126 and Day 168 in the absence of RBC transfusions, on three out of four measurements taken at the visits occurring in last six weeks
Time frame: Day 126 to Day 168
Proportion of Participants Who Remain Free From Transfusions
Number of participants with absence of administration of packed RBC transfusions between Day 1 and Day 168
Time frame: Day 1 to Day 168
Change From Baseline in Absolute Reticulocytes Count (ARC) Levels
Change from baseline in ARC levels as mean of visits between Day 126 and Day 168
Time frame: Baseline, Day 126 to Day 168
Percentage Change From Baseline in Lactate Dehydrogenase (LDH) Levels
Percentage change from baseline in LDH levels as mean of visits between Day 126 and Day 168
Time frame: Baseline, Day 126 to Day 168
Change From Baseline in Treatment Satisfaction Score Using TSQM-9 Questionnaire
Difference in scores of the Treatment Satisfaction Questionnaire for Medication(TSQM-9) between baseline and Day 84 and Day 168 assessed after switching from SoC (anti-C5) to iptacopan. TSQM-9 is a patient reported outcomes measure that was designed to assess patients' satisfaction with medication across three domains of effectiveness, convenience and global satisfaction. The TSQM-9 contains 3 questions in each domain. Domain scores range from 0 - 100 with higher scores representing better outcomes for the domain.
Time frame: Baseline, Day 84 and Day 168
Change From Baseline in Fatigue Score Using FACIT-F Questionnaire
Change from baseline in patient-reported scores for the functional assessment of chronic illness therapy - Fatigue (FACIT-F) collected at Day 84 and Day 168. The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.
Time frame: Baseline, Day 84 and Day 168
Percentage of Patients Who Had Breakthrough Hemolysis (BTH) Event
Wilson method is used to calculate the confidence interval for the proportion of patients who had events. The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs \& symptoms, in presence of laboratory evidence of intravascular hemolysis.
Time frame: Up to 168 Days
Percentage of Patients Who Had Major Adverse Vascular Events (MAVEs)
A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.
Time frame: Up to 168 Days
A total of 23 centers; 9 in United States, 4 in Germany, 3 in France, 2 in the United Kingdom, 2 in Italy and one each in Spain, Turkey and Republic of Korea enrolled participants.
| Milestone | LNP023 200mg b.i.d. |
|---|---|
| Started | 52 |
| Completed | 51 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Change in hemoglobin (Hb) levels as mean of visits between Day 126 and Day 168 compared to baseline. Baseline is defined as as the mean of three Hb assessments conducted at the central laboratory: two during screening and the third on Day 1. The estimation of change from baseline in Hb levels was handled by the hypothetical strategy where participants were assumed as if they did not receive RBC transfusions while on treatment (RBC transfusions were expected to be rare). Assuming that participants had stable Hb levels at study entry, the mean change from baseline in Hb level between Day 126 and Day 168 was expected to be unchanged should participants have continued on anti-C5 treatment. Non-inferiority of iptacopan was therefore tested by the null hypothesis (H0) against the alternate hypothesis (H1) comparing the mean change from baseline in Hb level in iptacopan between Day 126 and Day 168 (μ) to -1 g/dL: H0: μ \<= -1, H1: μ \> -1.
| g/dL | LNP023 200mg b.i.d. |
|---|---|
| Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority | 2.01 (1.74 to 2.29) |
Change in hemoglobin (Hb) levels as mean of visits between Day 126 and Day 168 compared to baseline. Baseline is defined as as the mean of three Hb assessments conducted at the central laboratory: two during screening and the third on Day 1.
| g/dL | LNP023 200mg b.i.d. |
|---|---|
| Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Superiority | 2.01 (1.74 to 2.29) |
Response defined as Hb ≥12 g/dL assessed between visits Day 126 and Day 168 in the absence of RBC transfusions, on three out of four measurements taken at the visits occurring in last six weeks
| Proportion of participants | LNP023 200mg b.i.d. |
|---|---|
| Proportion of Hematological Responders to Iptacopan Treatment | 92.7 (84.6 to 98.1) |
Number of participants with absence of administration of packed RBC transfusions between Day 1 and Day 168
| Proportion of participants | LNP023 200mg b.i.d. |
|---|---|
| Proportion of Participants Who Remain Free From Transfusions | 100.0 (93.1 to 100.0) |
Change from baseline in ARC levels as mean of visits between Day 126 and Day 168
| 10^9 cells/L | LNP023 200mg b.i.d. |
|---|---|
| Change From Baseline in Absolute Reticulocytes Count (ARC) Levels | -89.19 (-95.47 to -82.92) |
Percentage change from baseline in LDH levels as mean of visits between Day 126 and Day 168
| Percent change from baseline in LDH | LNP023 200mg b.i.d. |
|---|---|
| Percentage Change From Baseline in Lactate Dehydrogenase (LDH) Levels | -1.30 (-6.56 to 4.26) |
Difference in scores of the Treatment Satisfaction Questionnaire for Medication(TSQM-9) between baseline and Day 84 and Day 168 assessed after switching from SoC (anti-C5) to iptacopan. TSQM-9 is a patient reported outcomes measure that was designed to assess patients' satisfaction with medication across three domains of effectiveness, convenience and global satisfaction. The TSQM-9 contains 3 questions in each domain. Domain scores range from 0 - 100 with higher scores representing better outcomes for the domain.
| score on a scale | LNP023 200mg b.i.d. |
|---|---|
| TSQMS1-Effectiveness Day 84 | 15.08 (9.60 to 20.57) |
| TSQMS1-Effectiveness Day 168 | 12.54 (5.58 to 19.49) |
| TSQMS1-Convenience Day 84 | 20.34 (13.68 to 26.99) |
| TSQMS1-Convenience 168 | 23.86 (17.62 to 30.10) |
| TSQMS1-Global Satisfaction Day 84 | 14.26 (9.79 to 18.72) |
| TSQMS1-Global Satisfaction Day 168 | 18.53 (12.87 to 24.19) |
Change from baseline in patient-reported scores for the functional assessment of chronic illness therapy - Fatigue (FACIT-F) collected at Day 84 and Day 168. The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.
| score on a scale | LNP023 200mg b.i.d. |
|---|---|
| Day 84 | 4.88 (3.23 to 6.53) |
| Day 168 | 4.29 (1.74 to 6.85) |
Wilson method is used to calculate the confidence interval for the proportion of patients who had events. The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs \& symptoms, in presence of laboratory evidence of intravascular hemolysis.
| Percentage of patients with BTH events | LNP023 200mg b.i.d. |
|---|---|
| Percentage of Patients Who Had Breakthrough Hemolysis (BTH) Event | 0.00 (0.00 to 0.14) |
A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.
| Percentage of patients with MAVEs | LNP023 200mg b.i.d. |
|---|---|
| Percentage of Patients Who Had Major Adverse Vascular Events (MAVEs) | 0.00 (0.00 to 0.14) |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 7 days post treatment for non-serious AEs and 30 days post treatment for serious AEs if patient did not roll over to REP study, up to a maximum duration of 198 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LNP023 200mg b.i.d. | 0/52 (0%) | 2/52 (3.8%) | 25/52 (48.1%) |
| Event | LNP023 200mg b.i.d. |
|---|---|
| PyrexiaGeneral disorders and administration site conditions | 1/52 |
| Pneumonia bacterialInfections and infestations | 1/52 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/52 |
| Event | LNP023 200mg b.i.d. |
|---|---|
| HeadacheNervous system disorders | 9/52 |
| DiarrhoeaGastrointestinal disorders | 6/52 |
| NauseaGastrointestinal disorders | 6/52 |
| NasopharyngitisInfections and infestations | 6/52 |
| FatigueGeneral disorders and administration site conditions | 4/52 |
| Upper respiratory tract infectionInfections and infestations | 3/52 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/52 |
| Age, Categorical(Participants) | LNP023 200mg b.i.d. |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 48 |
| >=65 years | 4 |
| Age, Continuous(years) | LNP023 200mg b.i.d. |
|---|---|
| Mean | 46.0 ± 13.67 |
| Sex: Female, Male(Participants) | LNP023 200mg b.i.d. |
|---|---|
| Female | 20 |
| Male | 32 |
| Race/Ethnicity, Customized(Participants) | LNP023 200mg b.i.d. |
|---|---|
| White | 35 |
| Asian | 4 |
| Not Reported | 9 |
| Unknown | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2023 to primary completion in Oct 2024, 17 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 17 months is below that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iptacopan